Labcorp Holdings Inc. announces the retirement of Dr. D. Gary Gilliland from its board of directors, effective December 31, 2025.
Dr. Gilliland, a world-renowned physician-scientist and oncology executive, has been a valuable asset to Labcorp for over 10 years.
Labcorp expresses gratitude for Dr. Gilliland's unwavering commitment to advancing healthcare and improving lives.
Invaluable Contribution
Dr. Gilliland's extraordinary knowledge in oncology and gene therapy has significantly contributed to Labcorp's mission.
Strategic Leadership
Dr. Gilliland served on key committees and played a vital role in strengthening Labcorp's position as a global leader in laboratory services.
Experience and Expertise
With a background in prestigious institutions like Fred Hutchinson Cancer Research Center and Harvard Medical School, Dr. Gilliland brought extensive experience to Labcorp.
- Dr. Gilliland's retirement marks the end of an era of exceptional leadership at Labcorp.
- The company will need to identify a replacement with similar expertise to continue its trajectory of innovation and growth in the healthcare sector.
Labcorp recognizes Dr. Gilliland's significant contributions and looks forward to continuing its innovative work in healthcare with a renewed board structure.